Congratulations to Professor Bobby Gaspar of the UCL Great Ormond Street Institute of Child Health who has been named the new CEO of global gene therapy spinout [...]
About Lucy TuffinThis author has not yet filled in any details.
So far Lucy Tuffin has created 88 blog entries.
BioMarin’s Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020Lucy Tuffin2020-02-26T16:12:06+00:00
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics Licens [...]
UCLB spinout companies Odin Vision and Echopoint Medical received awards at the 2019 SEHTA MedTech Business Awards on Thursday 6 February, alongside guest speak [...]
London, 24 January 2020 SmartTarget Ltd, a spinout company of UCL which successfully brought to market image fusion technology allowing accurate targeting of pr [...]
Are you developing an innovative piece of technology or research idea, at UCL, that has the potential to benefit society? Perhaps your project could be the key [...]
DiNAQOR AG Announces Research Collaboration and License Agreement with UCL to Investigate Gene Therapies for Heart FailureLucy Tuffin2020-01-13T12:28:50+00:00
DiNAQOR AG, a global gene therapy platform company, today announced a research collaboration and exclusive license agreement with UCL to develop novel gene ther [...]
A FVIII gene therapy treatment, developed by world leading gene therapy expert, Professor Amit Nathwani at UCL has shown positive results in treating patients w [...]
Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, has announced Syncona Ltd (Syncona) has made an $ [...]
Abcam and SomaServe announce comprehensive partnership to realise the potential of PolyNaut® ‘bionic’ nanoparticles for delivery to live cellsLucy Tuffin2019-12-17T11:56:35+00:00
Abcam plc, a global innovator in life science reagents and tools, and SomaServe Ltd, a Pharma service and specialist reagent business exploiting PolyNaut® Techn [...]
BioMarin today announced it has submitted a marketing application to the European Medicines Agency (EMA), for the investigational gene therapy, valoctocogene ro [...]